Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), FGFRs antagonists(Fibroblast growth factor receptors antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | CN | 26 Oct 2023 | |
Bile Duct Neoplasms | Phase 1 | CN | 01 Jun 2022 | |
Bladder Cancer | Phase 1 | CN | 01 Jun 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 03 Dec 2021 | |
Advanced cancer | Phase 1 | CN | 12 Dec 2018 | |
Pancreatic Cancer | Phase 1 | CN | 12 Dec 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 Aug 2017 |
NCT04890795 (ASCO2023) Manual | Phase 1/2 | Small Cell Lung Cancer Third line | 30 | (zoqpghdywm) = vdxbeecqtz qujwafkxbc (gwuknnhuov ) View more | Positive | 26 May 2023 |